Introduction
The development of portal hypertension is a common consequence of chronic liver diseases and leads to the major complications of liver cirrhosis, such as ascites, hepatic encephalopathy, variceal bleeding, and decompensation. Furthermore, decompensation is the most important predictor of prognosis and mortality in patients with liver cirrhosis (1) . Thus, early diagnosis of portal hypertension is essential for adequate treatment to reduce the mortality rate of portal hypertension-related complications (2) .
Measurement of the hepatic venous pressure gradient (HVPG) has been accepted as the reference standard for portal hypertension assessment in patients with cirrhosis. Patients with clinically important portal hypertension (HVPG ≥ 10 mm Hg) are at increased risk of developing varices, while patients with severe portal hypertension (HVPG ≥ 12 mm Hg) are at risk for variceal bleeding, with mortality rates ranging from 20% to 35% (3).
However, measurement of HVPG is an invasive procedure associated with complications and is costly. Thus, there is a need for accurate and noninvasive methods of assessing the progression of portal hypertension.
Liver stiffness (LS) measured by using transient elastography is a rapid and noninvasive method for the diagnosis of portal hypertension in patients with liver cirrhosis (4-6). However, Vizzutti et al (4) confirmed a poor correlation between the HVPG and LS when the HVPG is greater than 12 mm Hg, and LS measurements obtained by using transient elastography have been considered a useful but not a suitable method for identifying esophageal varices (EVs) (7). Colecchia et al (8) have reported that measuring spleen stiffness (SS) by using transient elastography was another feasible method for identifying portal hypertension in patients with hepatitis C virus-induced cirrhosis. However, transient elastography has some limitations. Measuring LS with transient elastography is difficult in patients who are obese or who have narrow intercostal spaces and is impossible in patients with ascites (9).
Acoustic radiation force impulse (ARFI) imaging can be performed with clear observation of the actual measuring site with B-mode imaging and can be used even in obese patients and in patients with ascites (10-14). In our recent study (11) , SS evaluated by using ARFI imaging was shown to be closely correlated with the presence of EVs; however, that study did not have the reference standard of HVPG.
The aim of our current study was to evaluate the accuracy of SS and LS measured by using ARFI imaging in the diagnosis of portal hypertension in patients with liver cirrhosis, with HVPG as a reference standard.
Material and methods

Patients
This study was performed in accordance with the guidelines of and was approved by our institutional review board. Written informed consent was obtained.
Eighty patients with liver cirrhosis underwent assessment of portal pressure and endoscopic findings before starting prophylactic treatment with a β-blocker or endoscopic treatment; these patients were considered for inclusion in the study between February 2012 and August 2013 on being referred to the Kurashiki Central Hospital.
Of these 80 patients, 18 were excluded for the following reasons: episodes of recent (<6 months) gastrointestinal bleeding (n = 8), a history of splenectomy (n = 2), a history of partial splenic embolization (n = 2), a history of β-blocker therapy (n = 4), and the presence of portal thrombosis (n = 2) (Fig 1) . A diagnosis of cirrhosis was determined as described previously (12, 13) on the basis of the results of histologic examination of liver tissue or combined physical, laboratory, and radiologic findings.
ARFI measurements in each patient were obtained by using an ultrasonography (US) system (Acuson S2000; Siemens, Erlangen, Germany) by one of two sonographers (J.T. and A.S., with 10 and 15 years of experience, respectively) who were blinded to the clinical data. After an overnight fast, each patient was placed in the supine position and underwent ARFI imaging with B-mode imaging. A region of interest (a fixed-dimension 1 × 0.5-cm box; maximum evaluable depth, 5.5 cm) in the liver and spleen parenchyma that was free of large blood vessels was selected. LS was measured in the right lobe of the liver, 1 cm below the liver capsule, by using the intercostal approach. SS was measured 1 cm below the spleen capsule by using the intercostal approach. ARFI shear-wave velocity was measured in meters per second. According to previous reports (10,14,15), more than five successful measurements should be performed for each patient. Thus, five valid measurements were performed in the liver and in the spleen of each patient, and median values were calculated. LS or SS measurement failure was defined as when there were zero valid shots, and unreliable measurements were defined as when the ratio of the interquartile range to the median value was greater than 30% or when the success rate was less than 60% (9,16). The maximum spleen bipolar diameter was estimated by using US and was expressed in millimeters. Platelet count to spleen diameter ratio (PSR) (17) was calculated for all patients. Clinical and laboratory parameters were measured in each patient on the day of US, which included ARFI imaging.
Within 1 week (mean, 2.3 days; range, 1-6 days) after the measurement of LS and SS, HVPG measurements were performed in patients who had fasted overnight by a hepatologist (Y.T., with 18 years of experience with HVPG measurement) who was blinded to the US data. The right hepatic vein was catheterized percutaneously through the femoral vein, and pressure was recorded in both the wedged position and the free position with a 5-or 6-F balloon-tipped catheter (Terumo, Tokyo, Japan). HVPG was determined by subtracting the free hepatic vein pressure from the wedged hepatic vein pressure, and all measurements were performed in triplicate. Clinically important portal hypertension was defined as an HVPG of 10 mm Hg or greater, and severe portal hypertension was defined as an HVPG of 12 mm Hg or greater, according to the Baveno V criteria (18) .
After the US examinations, all patients also underwent screening upper gastrointestinal endoscopy, and the presence of EVs was determined by one of six endoscopists (each with more than 7 years of experience), who were blinded to the US data and HVPG. EVs were classified on the basis of the criteria for describing endoscopic findings of esophagogastric varices in Japan (19). The severity of EVs was classified as follows: A score of F1 indicated straight and small-caliber varices; a score of F2, beady varices; and a score of F3, tumor-shaped varices. Presence of a red color indicated a high risk of variceal bleeding. EVs in danger of rupture (high-risk EVs) were defined as F2 or F3 EVs or as F1 EVs with red color signs or Child-Pugh class C disease according to the Baveno V criteria (18) . Low-risk EVs were defined as F1 EVs without red color signs or Child-Pugh class C disease. If the patients had highrisk EVs or clinically important portal hypertension, administration of a β-blocker or endoscopic treatment was considered.
Complete evaluation for each patient (US and endoscopic measurements) was performed within 3 months (mean, 1.4 months; range, 1 day to 2.90 months).
Statistical Analysis
After we analyzed the normal or nonnormal distribution of the continuous variables with the Kolmogorov-Smirnov test, we examined differences between continuous and categoric variables using the Student t test (for normally distributed variables), the Mann-Whitney test (for nonnormally distributed variables), and the χ2 test. Variables found to be associated with the presence of clinically important portal hypertension and severe portal hypertension at univariate analysis (P < .05) were entered into multivariate backward stepwise logistic regression analysis. SS and LS were separately entered into each multivariate analysis because of the strong correlation between SS and LS (r = 0.689), which might cause errors in multivariate analysis.
Linear correlations between noninvasive parameters of portal hypertension and HVPG were assessed by using the Spearman rank-order correlation coefficient (r). To compare the performance of two correlation coefficients, we performed the Steiger Z test for correlated correlations within a population (20) . By convention, values greater than |1.96| are considered significant if a two-tailed test is performed.
Receiver operating characteristic curve analysis of the parameters was used to assess their diagnostic value for identifying clinically important portal hypertension, severe portal hypertension, EVs, and high-risk EVs. The method suggested by DeLong et al (21) was used to compare the areas under the receiver operating characteristic curve (AUCs) of various parameters of portal hypertension such as SS, LS, spleen diameter, platelet count, and PSR. The overall performance of the models was evaluated with the Nagelkerke R2 and the Brier score. A higher R2 and a lower Brier score indicate better discriminative performance (Brier scores range from 0 [perfect] to 0.25 [worthless]) (22) .
Diagnostic value was calculated by using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, positive likelihood ratio (PLR), and negative likelihood ratio (NLR). Cutoff values were chosen according to the aim of the screening test (to rule out the presence of any condition), choosing the lowest NLR. Data are given as means or as values with 95% confidence intervals (CIs). For all analyses, P < .05 was considered to indicate a statistically significant difference. Data were analyzed by using SPSS 16.0 J for Windows (SPSS, Chicago, Ill), MedCalc (MedCalc Software, Broekstraat, Mariakerke, Belgium), and R software, version 3.0.1.
Results
Baseline Characteristics of Patients with Liver Cirrhosis
Among the 62 patients who satisfied the inclusion criteria, two had an inconclusive SS measurement because the spleen was poorly visualized secondary to obesity or gastrointestinal gas. In total, there were 60 patients in the final analysis group. Table 1 shows the clinical, biochemical, endoscopic, and US characteristics of the 60 patients. The mean age was 70.8 years, 34 patients (56.7%) were male, and 36 patients (60.0%) had histologically proven cirrhosis. A total of 34 patients (56.7%) had clinically important portal hypertension, 29 (48.3%) had severe portal hypertension, 24 (40.0%) had EVs, and 16 (26.7%) had high-risk EVs.
Table 1 Baseline Patient Characteristics
Note.-Data are means 6 standard deviations or numbers of patients, with percentages in parentheses. AST = aspartate aminotransferase. * P = .99.
Clinical Parameters for Identifying Clinically Important Portal Hypertension and Severe Portal Hypertension
Platelet count, prothrombin time, albumin level, ALT level, Child-Pugh classification, LS, SS, and PSR were associated with the presence of clinically important portal hypertension according to univariate logistic regression analysis (P = .009, P = .012, P = .043, P = .005, P = .023, P < .001, P < .001, and P = .008, respectively) ( Table 2 ). SS was selected as an independent parameter associated with the presence of clinically important portal hypertension after adjustment for platelet count in multivariate logistic regression analysis (P < .001) ( Table 2) . Furthermore, LS was also selected as an independent parameter associated with the presence of clinically important portal hypertension after adjustment for ALT level in multivariate logistic regression analysis (P = .001).
Platelet count, prothrombin time, albumin, ALT level, Child-Pugh classification, LS, SS, spleen diameter, and PSR were significant parameters associated with the presence of severe portal hypertension in univariate logistic regression analysis (P = .007, P = .003, P = .022, P = .006, P = .002, P < .001, P < .001, P = .010, and P = .001, respectively) ( Table E1 [online]). SS was selected as an independent parameter associated with the presence of severe portal hypertension after adjustment for platelet count in multivariate logistic regression analysis (P < .001). Furthermore, LS was also selected as an independent parameter associated with the presence of severe portal hypertension after adjustment for ALT level and spleen diameter in multivariate logistic regression analysis (P = .001).
Table 2 Univariate and Multivariate Analysis of Clinical Parameters for Patients with HVPG Greater than 10 mm Hg
Note.-Data in parentheses are 95% CIs. AST = aspartate aminotransferase.
Correlations of SS, LS, and HVPG
Both SS and LS were strongly linearly correlated with HVPG (SS: r = 0.876; LS: r = 0.609) (Fig 2) . The correlation coefficient between SS and HVPG was significantly higher than that between LS and HVPG (P < .0001). In patients with an HVPG of 10 mm Hg or greater (n = 34), both SS and LS were significantly correlated with HVPG (SS: r = 0.764; LS: r = 0.426) (Fig 3) . The correlation coefficient between SS and HVPG was significantly higher than that between LS and HVPG (P = .017). In patients with an HVPG of less than 10 mm Hg (n = 26), there was a significant correlation between HVPG and SS (r = 0.451), while no correlation was observed between HVPG and LS (r = 0.034) (Fig 3) . 
AUCs of SS and Other Noninvasive Parameters for Identifying Clinically Important Portal Hypertension and Severe Portal Hypertension
Among these parameters, SS was the most accurate diagnostic factor for clinically important portal hypertension (AUC, 0.943; 95% CI: 0.852, 0.987) and severe portal hypertension (AUC, 0.963; 95% CI: 0.880, 0.995), and both AUCs of SS were significantly higher than those of LS, spleen diameter, platelet count, and PSR (P < .05 for all) ( Table 3) . Indicating its overall diagnostic performance for clinically important portal hypertension and severe portal hypertension, SS had high Nagelkerke R2 values (0.710 for clinically important portal hypertension and 0.770 for severe portal hypertension) and low Brier scores (0.100 for clinically important portal hypertension and 0.080 for severe portal hypertension) (Table 3 ).
Thus, SS had the best overall performance for the diagnosis of clinically important and severe portal hypertension.
Table 3 Performance of Clinical Parameters for Association with Portal Hypertension
Note.-Data in parentheses are 95% CIs.
AUCs of SS and Other Noninvasive Parameters for Identifying EVs and HighRisk EVs
SS was the most accurate diagnostic factor for EVs (AUC, 0.937; 95% CI: 0.844, 0.984) and high-risk EVs (AUC, 0.955; 95% CI: 0.867, 0.992) and both AUCs for association with EVs and high-risk EVs of SS were significantly higher than those of LS, spleen diameter, platelet count, and PSR (P < .05 for all for both parameters) (Table E2 [online]).SS had high Nagelkerke R2 values (0.684 for EVs and 0.717 for high-risk EVs), low Brier scores (0.099 for EVs and 0.081 for high-risk EVs) (Table E2 [online]).
Diagnostic Ability of SS for Identifying Clinically Important Portal Hypertension, Severe Portal Hypertension, EVs, and High-Risk EVs
The SS cutoff values of 3.10, 3.15, 3.36, and 3.51 m/sec were selected to rule out the presence of clinically important portal hypertension, severe portal hypertension, EVs, and high-risk EVs (sensitivity, 97.1%, 96.6%, 95.8%, and 93.8%, respectively; NLR, 0.051, 0.056, 0.054, and 0.074, respectively) ( Table 4) .
Table 4 Cutoff Values and Diagnostic Accuracies of SS for Association with Portal Hypertension and EVs
Note.-Data in parentheses are percentages, with 95% CIs in square brackets.
Among 24 patients with EVs, 23 (95.8%) had high SS values (≥3.36 m/sec) (Fig 4) , while one patient had a low SS value (3.18 m/sec) and had small EVs without the red color sign. No high-risk EV was misdiagnosed with the SS cutoff value at 3.36 m/sec, which was proposed to rule out EVs. Moreover, no EVs were observed when the SS cutoff value was set at 3.10 m/sec, which was proposed to rule out clinically important portal hypertension. 
Discussion
We found that the AUCs of SS for identifying clinically important portal hypertension, severe portal hypertension, EVs, and high-risk EVs were excellent (0.943, 0.963, 0.937, and 0.955, respectively). Similar to results of previous studies (23, 24) , our results showed that the AUC for identifying EVs with LS measured at ARFI imaging was 0.789, and LS was therefore considered useful, but not excellent.
Thus, these results suggest that, in most patients evaluated by using SS, SS could be used to diagnose clinically important portal hypertension and severe portal hypertension associated with EVs and high-risk EVs. Thus, if our results are corroborated by future prospective studies, SS could potentially be used as an indication for screening endoscopy and prophylactic treatments such as β-blocker therapy or endoscopic variceal ligation. Moreover, the SS cutoff value of 3.51 m/sec proposed to rule out high-risk EVs was able to exclude the EVs in danger of rupture with a sensitivity of 93.8% and an NLR of 0.074.
Furthermore, no high-risk EVs were misdiagnosed with the SS cutoff value of 3.36 m/sec proposed to rule out EVs, and no EV was observed when the SS cutoff value was less than the 3.10 m/sec proposed to rule out clinically important portal hypertension.
In this study, we clearly demonstrated that the correlation coefficient between SS and HVPG was significantly higher than that between LS and HVPG (r = 0.876 vs r = 0.609, P < .0001). Furthermore, the correlation coefficient between SS and HVPG was significantly higher than that between LS and HVPG (r = 0.764 vs r = 0.426, P = .017) in patients with an HVPG of 10 mm Hg or greater.
A few investigators have assessed the correlation coefficient between SS and HVPG. Hirooka et al (27) reported that although both SS and LS values obtained by using real-time tissue elastography were linearly correlated with HVPG, the r value was higher for SS than for LS (r = 0.854 and r = 0.510, respectively). Colecchia et al (8) concluded that both SS and LS values obtained by using transient elastography were strongly correlated with HVPG (r = 0.885 and r = 0.836, respectively). However, these previous studies did not provide the statistical comparison of the strength of the two correlation coefficients (SS and HVPG vs LS and HVPG). Talwalkar et al (28) suggested that SS values greater than 10.5 kPa measured at magnetic resonance elastography in compensated cirrhosis were associated with EVs in all patients. These results indicate that additional assessment of SS may be better than measuring LS for identifying portal hypertension and EVs.
In a systematic review (29) of 12 studies of the diagnostic accuracy of transient elastography-based LS measurements, the diagnostic odds ratios for detecting the presence of any EV and large EVs were 7.5 (95% CI: 4.5, 12.7) and 8.8 (95% CI: 5.9, 13.2), respectively. Comparable diagnostic odds ratios for SS were 19.3 and 12.6, respectively, and the diagnostic performance of SS was significantly better than that of LS. SS is potentially characterized by a wider range of applications than is LS, because SS directly reflects the hemodynamic changes of extrahepatic factors caused by increases in portal pressure such as hyperdynamic splanchnic circulation and portosystemic collateral vessels (4, 8, 29) . An elevated SS value may be caused not only by congestion of the red pulp and tissue hyperplasia but also by diffuse fibrosis of spleen trabeculae (30,31).
Vizzutti et al (4) reported that strong correlation between HVPG and LS was observed in patients with an HVPG of less than 10 mm Hg and in those with an HVPG of less than 12 mm Hg (r = 0.81, P < .0001 and r = 0.91, P < .0001, respectively). In contrast, in our study, there was poor correlation between HVPG and LS in patients with an HVPG of less than 10 mm Hg (r = 0.034, P = .869).
An important clinical advantage of the ARFI device is that the success rate of ARFI measurements is higher than that of transient elastography measurements (33, 34) . In fact, the rates of unsuccessful measurements of LS and SS at ARFI imaging in our study were 0% and 3.2%, respectively. In contrast, rates of unsuccessful measurements of LS and SS at transient elastography have been reported to be 18.9% (9) and 14.6% (23), respectively. Furthermore, in a prior study (11) , we showed that LS and SS measurements consistently had excellent reproducibility, with intraobserver and interobserver agreement intraclass correlation coefficients of ARFI measurements of 0.97 and 0.97 for LS and 0.98 and 0.98 for SS, respectively.
We found that SS measurement at ARFI imaging had a high diagnostic performance for defining the degree of portal hypertension (HVPG ≥ 10 or ≥ 12 mm Hg). However, our study was a cross-sectional study. More recently, Colecchia et al (35) reported that SS value obtained by using transient elastography represented an accurate predictor of clinical decompensation, with accuracy at least equivalent to that of HVPG, in patients with compensated cirrhosis in a longitudinal cohort study. Therefore, a longitudinal cohort study needs to be performed of the prediction of complications of cirrhosis with ARFI imaging.
The limitations of this study included the facts that the sample size of 60 participants was relatively small, the timing of SS measurements was not fixed, and this was a single-center study without external validation. We used the current population to set our thresholds for analysis, which can lead to an overestimation of results.
In conclusion, SS measured by using ARFI imaging provides excellent diagnostic performance for identifying portal hypertension in liver cirrhosis. Our findings are complementary to those of previous studies that suggest a role for SS measurements in the treatment of patients with liver cirrhosis. The measurement of SS could help select suitable patients for procedures such as screening endoscopy or prophylactic treatment for decompensation.
